QualityDipStocks / Health Care · Medical Specialities
Henry Schein HSIC
Outside our quality screen, so we don’t track its dips. It’s 7% below its 52-week high.
Outside our quality screen, trading near our fair value estimate.
- Fair value est.
- $78.82−7%
- Market Value
- $85.09at the price
- Off 52-wk high
- −7%
- Risk vs market
- Lowbeta 0.46
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $84.88
- 52-wk lowlowest close, 1 year$62.90−25.9%
- Fair value est.base case$78.82−7.1%
- PriceFri Oct 30 close$84.88you are here
- Market Valueavg paid since Sep 22$85.09+0.2%
- 52-wk highhighest close, 1 year$90.86+7.0%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, HSIC’s free cash flow would need to grow about 4% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much HSIC moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.0× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.46
- Volatility
- 26% vs 13% SPY
- Correlation SPY
- 0.23
- Correlation QQQ
- 0.08
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
Cash returnsShare count down 6.7% in a year: $728M of buybacks over 12 months.
Cash returnsFree cash flow grew 50% over the last 12 months vs the 12 months before.
ValuationFree-cash-flow yield of 5.9% (price / FCF 17.1×): $569M of free cash in the last 12 months.
ValuationEV/EBITDA of 12.9×, below the 17.0× median for the 55 Health Care companies we cover.
Top bearish points 5 of 5
Balance sheetDebt rose 32% to $3.1B from FY2023 to FY2025.
Balance sheetDebt / equity of 1.1×, above the 0.7× median for the 67 Health Care companies we cover.
GrowthSales grew 1.4% a year over the last three fiscal years, below the 7.3% median for the 101 Health Care companies we cover.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 3.4× EBITDA (limit 3×).
RiskReports earnings Nov 3 (consensus EPS $1.34): results can move the price sharply and reset Market Value.
Who’s talking about it
Notable investors, executives, analysts and public figures on Henry Schein in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical Specialities
All fundamentals
P/E 24.1 · FCF yield 5.9% · ROE 12%
Valuation
- P/E
- 24.1×Health Care median 29.2×
- Price / FCF
- 17.1×
- FCF yield
- 5.9%
- EV / EBITDA
- 12.9×
- Price / sales
- 0.71×
- Price / book
- 3.08×
- Market cap
- $9.7Bprice × diluted shares
- Enterprise value
- $13.0B
Growth
- Revenue, 12 months
- $13.6B
- Sales growth, 12 months
- +6.5%vs the 12 months before
- Sales growth, 3 yrs
- +1.4%/yrfrom FY2022
- Diluted EPS, 12 months
- $3.43
- EPS growth, last FY
- +7.2%
- Net income, 12 months
- $403M
- Net income growth
- +4%12 months vs before
Profitability
- Gross margin
- 31.3%
- Operating margin
- 5.0%
- Net margin
- 3.0%
- FCF margin
- 4.2%
- Return on equity
- 12%
- Return on invested capital
- 8%
Balance sheet
- Cash & short-term inv.
- $157M
- Total debt
- $3.5B
- Net cash
- −$3.3B
- Debt / equity
- 1.10×
- Interest coverage
- 4.3×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $569M
- FCF growth, 12 months
- +50%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $728M7.5% of market cap
- Share count, 1 year
- −6.7%diluted shares vs a year ago
- Stock-based comp
- $39M
Trailing 12 months to Jun 27, 2026; balance sheet at Jun 27, 2026. From Henry Schein’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $78.82 · MV $85.09 · FCF value $99.47
Assumes 3.0% growth for 5 years (revenue grew 1.4% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $4.97 a share (trailing 12 months to Jun 27, 2026), from the 10-Q filed Aug 4, 2026.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 48 · 5 days −0.1%
The business
FCF $0.5B · Sales +7%
- Free cash flow, 12 months$0.5B
- Free-cash-flow yield4.7%
- Free-cash-flow margin3%
- Gross margin31%
- Operating margin6%
- Return on invested capital9%
- Return on equity9%
- Sales growth (latest quarter vs year-ago quarter)+7%
- Net debt / EBITDA3.4×
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$1.34
- Year-ago EPS$1.38
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
HSIC is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.